Diabetes Research and Clinical Practice
Volume 86, Issue 1 , Pages 61-66 , October 2009

The impact of family history of type 2 diabetes on pancreatic β-cell function

Received 4 April 2008 ,Revised 3 March 2009 ,Accepted 2 April 2009.

References 

  1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  2. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr. Rev. 1998;19:477–490
  3. Elbein SC, Wegner K, Kahn SE. Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care. 2000;23:221–227
  4. Larsson H, Ahren B. Islet dysfunction in obese women with impaired glucose tolerance. Metabolism. 1996;45:502–509
  5. Buchanan TA, Xiang AH, Kjos SL, Triqo E, Lee WP, Peters RK. Antepartum predictors of the development of type 2 diabetes in Latin women 11–26 months after pregnancies complicated by gestational diabetes. Diabetes. 1999;48:2430–2436
  6. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 1999;104:787–794
  7. Cnop M, Vidal J, Hull RL, Utzschneider KM, Carr DB, Schraw T, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care. 2007;30:677–682
  8. Haupt A, Staiger H, Schäfer SA, Kirchhoff K, Guthoff M, Machicao F, et al. The risk allele load accelerates the age-dependent decline in beta cell function. Diabetologia. 2009;(January):[Epub ahead of print]
  9. The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(Suppl. 1):S5–S20
  10. D. Porte Jr., R.S. Sherwin, Ellenberg & Rifkins's Diabetes Mellitus, fifth edition, 2000, p. 420.
  11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  12. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE and the American Diabetes Association GENNID Study Group. β-Cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S.. Diabetes. 2002;51:2170–2178
  13. Hanson RL, Pratley RE, Bogardus C, Narayan KM, Roumain JM, Imperatore G, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am. J. Epidemiol. 2002;151:190–198
  14. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J. Clin. Invest. 1981;68:1456–1467
  15. Bergman RN, Ader M, Huecking K, Citters GV. Accurate assessment of β-cell function. The hyperbolic correction. Diabetes. 2002;51(Suppl. 1):S212–S220
  16. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Berqman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and β-cell function in human subjects: evidence for a hyperbolic function. Diabetes. 1993;42:1663–1672
  17. Guangwei L. Recognition of the evaluation of the pancreatic β cell function. Foreign Med. Sci.: Subvolume Endocrinol. 2005;25:164–189
  18. Kahn SE. Regulation of β-cell function in vivo: from health to disease. Diabetes Rev. 1996;4:372–389
  19. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE. Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J. Clin. Endocrinol. Metab. 1999;84:1398–1403
  20. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, et al. Pancreatic β-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995;273:1855–1861
  21. Hattersley AT. Prime suspect: the TCF7L2 gene and type 2 diabetes risk. J. Clin. Invest. 2007;117:2077–2079
  22. Lyssenko V, Lupi R, Marchetti P, Guerra SD, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 2007;117:2155–2163

☆ This work was supported by The National 863 Project of China (2004AA07) and The Chongqing Health Bureau Project (032080).

PII: S0168-8227(09)00152-1

doi: 10.1016/j.diabres.2009.04.004

Diabetes Research and Clinical Practice
Volume 86, Issue 1 , Pages 61-66 , October 2009

Article Tools

* Image Usage & Resolution